Corcept Therapeutics price target raised to $67 from $38 at Piper Sandler

Piper Sandler earlier today raised the firm’s price target on Corcept Therapeutics to $67 from $38 and keeps an Overweight rating on the shares. Following a a survey of endocrinologists, the firm believes the Cushing’s syndrome space is poised to continue its expansion post Corcept’s presentation of prevalence data from the Phase IV CATALYST study. Endocrinologists envision a fairly wide patient footprint for relacorilant in the wake of the presentation of data from the Phase III GRACE study, the analyst tells investors in a research note. Piper upped estimates for Corcept’s Cushing’s syndrome franchise and continues to expect relacorilant will drive much of the company’s sales growth over time.